Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Andrew Haas

Dr. Andrew Haas

Director, Interventional Pulmonary and Thoracic Oncology Program

Dr. Andrew R. Haas has expertise in asbestos-related disease, playing a key role in the Mesothelioma and Pleural Disease Program at Penn Medicine and the Abramson Cancer Center.

Get in touch
Jump to a Topic:

About Andrew Haas

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Team Leader icon

    Team Leader

  • Works for Specialty Center icon

    Works for Specialty Center

  • Board Certified icon

    Board Certified in Pulmonary Medicine

As an interventional pulmonologist focused on thoracic oncology, Haas treats various lung and pleural diseases.

He performs diagnostic procedures on patients with suspected malignancies, a subspecialty of pulmonary critical care medicine.

Haas also has become a leader in the early development of chimeric antigen receptor (CAR) T-cell therapy, which involves a laboratory reprograming of a patient’s own white blood cells to help stop cancers such as mesothelioma.

CAR T-cell therapy already has shown considerable promise with certain blood cancers like leukemia, a big step toward a potential new approach to treatment of other malignancies.

Its effectiveness with solid tumors such as mesothelioma has been limited, but early research has been promising.

Studying Gene Therapy and Immunotherapy

Haas is the principal investigator of a clinical trial at Penn Medicine trying to determine the best way to utilize CAR T-cell therapy in the fight against pleural mesothelioma.

“We do not anticipate CAR T-cells to work as well in mesothelioma due to the complex tumor environment in solid tumors,” Haas said. “But we will move to combination therapy with other immune or tumor microenvironment modifying drugs to improve efficacy.”

He is overseeing another clinical trial exploring the safety of combining this customized gene therapy with chemotherapy in patients with pleural mesothelioma.

He believes immunotherapy is changing the way most cancers are treated, often using it in combination with other modalities.

“We need a more multi-modality approach to treatment. Immunotherapy is further along than it was a few years ago,” he said. “Each immune system is unique. This concept of precision medicine will be part of immunotherapy and how we understand which therapies are best for the individual patient.”

Serves Several Programs at UPenn

Haas serves as the bronchoscopy director at the University of Pennsylvania Hospital and an associate professor of medicine at UPenn.

His specialties include all asbestos-related lung diseases, airway stenting, lung volume reduction surgery, therapeutic endoscopy, tracheal stenosis and laser bronchoscopy.

He is part of the Lung Nodule Program, the Lung Cancer Program, the Interventional Pulmonology Program and the much-heralded Mesothelioma and Pleural Disease Program, which can offer every treatment option available worldwide — and a few available only there.

A key aspect of the Mesothelioma and Pleural Disease Program is the weekly meeting of experts from different specialties to help personalize therapy for each patient.

Disclaimer: Dr. Andrew Haas has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Daniel King, Content Writer for
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Penn Medicine. (n.d.). The Mesothelioma and Pleural Program.
    Retrieved from:
  2. Penn Medicine. (n.d.). Andrew R. Haas, MD, PhD.
    Retrieved from:
  3. (2019, Feb. 26). CART-meso in Mesothelin Expressing Cancers. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified July 24, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now